Effects of 2,3-Dideoxyinosine on Toxoplasma gondii Cysts in Mice

Abstract : The activity against Toxoplasma gondii of 2,3 dideoxyinosine (ddI), an anti-human immunodeficiency virus drug, was examined in an in vitro and in vivo study. Cell cultures infected with a strain known to cause chronic infections were used to show the dose-dependent effect of this drug compared with spiramycin and sulfadiazine. When a dose of 4 g/ml was used, no infected THP-1 cells or parasites were found after 60 h of incubation. An electron-microscopic study confirmed that after 12 h at 1 g/ml, the few parasites observed were severely altered. The treatment of chronically infected mice 3 months postinfection showed that a 30-day treatment with 2 mg of ddI/ml induced a significant reduction in the number of T. gondii cysts in the cerebral tissue. These cysts were not viable, as confirmed by immunofluorescence and reinfection experiments. These experiments suggest a possible role for ddI in the treatment of toxoplasmosis, and this possibility deserves further investigation.
Complete list of metadatas

https://hal-univ-lyon1.archives-ouvertes.fr/hal-02110926
Contributor : Philippe Lawton <>
Submitted on : Friday, April 26, 2019 - 4:16:40 PM
Last modification on : Saturday, April 27, 2019 - 1:01:48 AM

File

10-Sarciron 97 modifié.pdf
Files produced by the author(s)

Identifiers

Collections

Citation

Marie-Elisabeth Sarciron, Philippe Lawton, Charles Saccharin, Anne-Françoise Pétavy, François Peyron. Effects of 2,3-Dideoxyinosine on Toxoplasma gondii Cysts in Mice. Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 1997, 41 (7), pp.1531-1536. ⟨10.1128/AAC.41.7.1531⟩. ⟨hal-02110926⟩

Share

Metrics

Record views

19

Files downloads

29